Investigators from University Medical Center Rostock Report New Data on Melanoma (Correlation of Baseline Tumor Burden With Clinical Outcome In Melanoma Patients Treated With Ipilimumab).

Předmět:	ACADEMIC medical centers IPILIMUMAB MELANOMA PROGNOSIS PROGRESSION-free survival
Zdroj:	Immunotherapy Weekly; 9/19/2023, p832-832, 1p
Abstrakt:	Keywords: Rostock; Germany; Europe; Biotechnology; Cancer; Drugs and Therapies; Health and Medicine; Immunologic Agents; Immunotherapy; Ipilimumab Therapy; Melanoma; Monoclonal Antibodies; Oncology; Pharmaceuticals; Yervoy Therapy EN Rostock Germany Europe Biotechnology Cancer Drugs and Therapies Health and Medicine Immunologic Agents Immunotherapy Ipilimumab Therapy Melanoma Monoclonal Antibodies Oncology Pharmaceuticals Yervoy Therapy 832 832 1 09/19/23 20230919 NES 230919 2023 SEP 22 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Research findings on Oncology - Melanoma are discussed in a new report. According to the news reporters, the research concluded: "Using calculated BTB as a definition of tumor burden may help to increase comparability of outcome of therapies in future studies.". [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu